Pinned Tweet
Less really is more. Next for us: target selection for early stage solid tumors with @AnthropicAI
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency đź§µ
Jason retweeted
Brain maps usually show genes or cell types. Membrane lipids, which are essential for synaptic transmission and whose altered composition is linked to many brain diseases, remained poorly mapped by comparison. Fusar Bassini, La Manno and colleagues asked whether lipids simply follow the brain’s known anatomy or reveal an organization of their own.
They measured 172 lipids across the whole mouse brain and found 539 chemically distinct territories, which they call lipizones. Most overlap known cell-type territories, but lipid patterns could be only partly predicted from gene expression. Regions connected by axons, even distant ones, were more likely to share lipid signatures. In pregnant mice, the white matter and specific cortical territories changed their lipid composition.
The map is public, so other labs can use it to locate where lipid changes occur in disease, which gene-expression maps cannot show. As a descriptive resource, it does not test what these territories do for neural function, and the pregnancy comparison rests on a small number of mice.
Fig. 1 from Fusar Bassini et al. (2026), Nature. CC BY 4.0.
Jason retweeted
Whole in One: Expansion microscopy + machine learning combined in WHOLISTIC – a means to image networks of cellular activity body wide
📹 Virginie M. S. Ruetten et al @HHMIJanelia in @Nature
➡️ bpod.org.uk/archive/2026/10/… with @DrJohnAnkers
Jason retweeted
The "Age of Miracles" era:
I took a look inside Anthropic's latest progress in the life sciences, including working with a ton of biopharma partners and a new acquisition disclosure
All coming before what is likely the business world's largest IPO:
endpoints.news/anthropic-pit…
Jason retweeted
Great analysis from @owl_posting as always.
Expanding a bit on our work @generate_biomed particularly on the literature, novelty, and creativity đź§µ
Incredibly cool to see. This + the one-man biotech acquisition by Anthropic are lead indicators of the future
AI will spawn a thousand flowers in biology. “Why not me?”
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency đź§µ
Jason retweeted
Making medicines is really hard. Excited to share some early work from the team @generate_biomed with our partners @AnthropicAI on how we can leverage agentic tools to rapidly advance science. While it is still early days, the signals are very promising and patients are waiting.
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
anthropic.com/research/early…
Jason retweeted
I've been hanging out with this rock star team at @generate_biomed for the past few weeks and while this result is worth a deep dive, the way they work is the real game changer. They've allowed AI to remove the friction in the organization. As AI-pilled as I am, it's taken some adapting to transform to the way the future will look, but there is no catering to the 'old' way.
And that's the only way the true impact of AI will be seen, not just in the frontier labs, but also in the AI native biotechs working to bring real cures to patients fater.
Things are going to change quickly and the hardest part is going to be how people and systems adapt to move at speed. And this team is doing it.
Congrats @jasonyi96, @liambai21, @wwang002, @KaggenA!
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency đź§µ
Jason retweeted
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
anthropic.com/research/early…
Jason retweeted
A smaller CAR T-cell receptor could make room for a more capable therapy.
In our collaboration with @AnthropicAI, six of our scientists used @claudeai alongside our own models, computational tools, and wet lab data to refactor a CAR T-cell receptor for solid tumors.
The redesigned signaling component was about 70% shorter than a standard design, making room for new functions and improving cancer-cell killing in laboratory tests. Watch how our scientists turned years of work into months, at a fraction of the cost, expanding what we can engineer for patients.
@AnthropicAI's case study → anthropic.com/research/early…
Our preprint → generatebiomedicines.com/pub…
Our blog → generatebiomedicines.com/blo…
Jason retweeted
Public preview of BioEmu2! @MSFTResearch AI for Science’s new foundation model for biomolecular structure, dynamics and function. Open weights, MIT license.
github.com/microsoft/bioemu2
Movie: BioEmu2-simulated binding of intrinsically disordered peptide PUMA to MCL-1 receptor. 🧵⬇️
Jason retweeted
Excited to share what we’ve been building with Chaperone!
In our benchmark, Chaperone reduced token usage by 86%. We also went from hypothesis to sequences ready for wet-lab testing in just two weeks—yielding a 1.32 nM cortisol binder in the first experimental round!
Jason retweeted
Today we are excited to release Artios, a fully open source system for designing functional de novo enzymes.
Enzymes present a new frontier for de novo protein design models due to the challenge of coordinating precise chemistry, rather than binding a target.
Enzymes are life’s biological machines and by designing them we can truly start to engineer biology.
We believe these fundamental capabilities should be built in the open and shared with the community to progress science faster.
đź§µ 1/6
Jason retweeted
1/ We discovered something totally unexpected about the neural structure of consciousness that overturns decades of thinking on its biological basis and brings us significantly closer to the recipe for generating conscious awareness.
New preprint: biorxiv.org/content/10.64898… (led by @HesseJanis, with @FrankLanfranchi, @_conor_mcgrory, @Yuelin_Shi, and @EngelTatiana)
Jason retweeted
Introducing Prime Agent:
A self-improving RLM harness for coding and long-running autonomous tasks.
Designed to be both token-efficient and expressive through programmatic tool calling, context as a variable, multi-agent messaging, and a self-modifiable harness state.
Jason retweeted
Sonoluminescence - If you collapse an underwater bubble with a soundwave, light is produced, and nobody knows why
Jason retweeted
Annual killifish make neutrophils before almost every other cell type, even before gastrulation. Neutrophils usually arise from the lateral plate mesoderm (forming in cyan), but in killifish they are already patrolling around the embryo in gold. tinyurl.com/killiphil
Jason retweeted
After AlphaGo, the skill of human Go players noticeably improved. I suspect we will see a similar pattern in math.
A complete cell image by chatGPT Image 2.0 🔥
🤖 Made with AI
































